Semaglutide Research: Mechanism, Evidence and Science

Semaglutide Research: Mechanism, Evidence and Science
Reading Time: 7 mins

Science & Medicine Obesity Cardiovascular Pharmacology
Investigative Science Report The Original: How Semaglutide Built the Evidence Base That Every Newer Drug Is Still Chasing In November 2023, semaglutide achieved what no obesity drug had ever achieved: a 20% reduction in major cardiovascular events in people with obesity but without diabetes. That finding repositioned obesity itself as a modifiable cardiovascular risk factor — and set a benchmark tirzepatide and retatrutide are still working to match.
2025–2026 · Science Desk ·
What It Is: The Molecule That Started the Modern Era Semaglutide is a synthetic analogue of the human glucagon-like peptide-1 (GLP-1) hormone, developed by Novo Nordisk. It shares approximately 94% sequence homology with native GLP-1(7-36), but two modifications transform it from a molecule with a half-life of minutes into one that persists for approximately 165–168 hours — long enough for once-weekly dosing. First, a single amino acid substitution at position 8 blocks cleavage by DPP-4, the enzyme that degrades native GLP-1. Second, a C-18 fatty diacid chain attached at position 26 enables binding to albumin in the bloodstream, dramatically extending circulation time. GLP-1 receptors are expressed in the pancreatic beta cells (stimulating glucose-dependent insulin secretion), the gut (slowing gastric emptying), the hypothalamus and brainstem (suppressing appetite and inducing satiety), and also in the heart, kidneys, liver, and lungs. This distribution explains why a drug designed for blood sugar ends up reducing heart attacks, protecting kidneys, and potentially influencing neurological disease. When semaglutide binds GLP-1 receptors in the hypothalamus and brainstem, it reduces food intake through a distributed network of neural pathways — not simply by making the stomach feel full. This is why the drug works even in patients who have had bariatric surgery. What the Trials Show
SUSTAIN-6 — Type 2 Diabetes, CV Safety · NEJM, 2016 3,297 patients with T2D at high cardiovascular risk. Semaglutide demonstrated a significant 26% relative reduction in the primary composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke. FDA approved injectable semaglutide (Ozempic) for T2D in December 2017.
STEP 1 — Obesity Without Diabetes · NEJM, 2021 1,961 adults, 68 weeks. Semaglutide 2.4 mg produced average weight loss of 14.9% vs. 2.4% placebo. 86% of participants achieved at least 5% weight loss; roughly one-third lost 20% or more. Prior obesity pharmacotherapy produced ~7–8% placebo-subtracted weight loss — semaglutide nearly doubled this benchmark. FDA approved Wegovy for chronic weight management in June 2021.
SELECT — Cardiovascular Outcomes in Obesity · NEJM, 2023 17,604 patients with pre-existing cardiovascular disease and obesity but without diabetes. Mean follow-up 39.8 months. Semaglutide produced a 20% relative risk reduction in the primary composite endpoint: 6.5% vs. 8.0% in placebo (HR 0.80; P<0.001). All-cause mortality was 19% lower. The cardiovascular benefit was independent of weight loss magnitude and baseline HbA1c — confirming pleiotropic mechanisms beyond glycemic or weight effects.
FLOW — Chronic Kidney Disease in T2D · NEJM, 2024 3,533 patients, median follow-up 3.4 years, stopped early for clear positive efficacy. Semaglutide reduced the primary composite kidney endpoint by 24% (HR 0.76; P=0.0003). Annual eGFR decline slowed by 1.16 mL/min/1.73m² per year. All-cause mortality reduced by 20%, cardiovascular events by 18%. The first dedicated kidney outcomes trial of any GLP-1 receptor agonist.
STEP-HFpEF — Heart Failure with Preserved Ejection Fraction · NEJM, 2023 529 patients with obesity-related HFpEF without T2D. Semaglutide 2.4 mg produced significant improvements in heart failure symptom scores and body weight, reducing heart failure hospitalization risk and improving functional capacity.
EVOKE/EVOKE+ — Alzheimer's Disease · A Significant Negative Result, 2025 ~1,800 patients with early-stage Alzheimer's, oral semaglutide 14 mg, two years. Results announced November 2025: no significant difference from placebo on the primary cognitive endpoint (CDR-SB score), despite improvements in some CSF biomarkers. A 2024 target-trial emulation using 1.09 million electronic health records had found lower rates of Alzheimer's diagnosis in T2D patients on semaglutide — but established disease pathology at the symptomatic stage appears not to be reversible by GLP-1 agonism. Prevention studies in cognitively normal adults continue.
Weight Regain on Discontinuation The STEP 1 extension followed participants for 48 weeks off semaglutide after completing the trial. Approximately two-thirds of lost weight returned within one year, along with reversal of most cardiometabolic gains. This mirrors the SURMOUNT-4 data for tirzepatide and reflects the same underlying biology: semaglutide manages obesity while it is administered. It does not permanently alter the set point. Semaglutide vs. Tirzepatide vs. Retatrutide
Semaglutide — Single GLP-1 Agonist ~14.9% weight loss at 68 weeks. The deepest outcomes evidence base: completed CV trials in T2D and obesity (SELECT — 20% cardiovascular event reduction), the first dedicated GLP-1 kidney outcomes trial (FLOW), HFpEF benefits, and real-world data from millions of patients. FDA-approved for T2D (2017), obesity (2021), adolescent obesity (2022).
Tirzepatide — Dual GLP-1/GIP Agonist ~22.5% at 72 weeks; 20.2% vs. semaglutide's 13.7% in direct head-to-head (SURMOUNT-5, NEJM 2025). 93% relative T2D risk reduction at 3 years. FDA-approved for T2D, obesity, and OSA. CV outcomes trial (SURMOUNT-MMO) expected 2027.
Retatrutide — Triple GLP-1/GIP/Glucagon Agonist ~28.7% at 68 weeks in Phase 3 (TRIUMPH-4, December 2025). Liver fat reduction of 82% in MASLD at 24 weeks — a glucagon-specific hepatic effect neither predecessor replicates. Not yet approved anywhere. Seven additional Phase 3 trials pending in 2026. FDA submission expected late 2026–early 2027.
The question of whether a drug actually reduces heart attacks and saves lives — with 17,604 patients and four years of follow-up behind it — has only one answer in this class, and that answer still belongs to semaglutide.
What Remains Unresolved The cardiovascular mechanism. SELECT showed CV benefit independent of weight loss. Whether the driver is anti-inflammation, visceral fat reduction, direct endothelial GLP-1 receptor effects, or some combination remains incompletely understood — and matters for predicting benefit across different patient subgroups. Thyroid cancer class warning. All GLP-1 receptor agonists carry a boxed warning for medullary thyroid carcinoma based on rodent studies. No human signal has been detected in SELECT or other large trials. Long-term pharmacovigilance continues. Children and adolescents. STEP TEENS showed strong efficacy in adolescents. Long-term effects on development, bone density, and pubertal progression require ongoing follow-up. Chronic treatment reality. Two-thirds of weight returns within a year of stopping. Treating obesity with semaglutide means treating it continuously — potentially for life. The infrastructure, access, and economic implications of this at population scale are unresolved. The Context the Numbers Don't Capture For decades, weight-loss pharmacotherapy was a graveyard of withdrawn drugs that were effective at weight loss but harmful to the heart. Semaglutide inverted this entirely: it produces the best weight loss ever seen from a pharmacological agent at the time of its approval, and simultaneously reduces cardiovascular events by 20%. That combination had never been demonstrated before. The analogy to statins is not hyperbolic. Like statins, semaglutide has a clear mechanism, robust randomized trial infrastructure, proven hard outcomes, and a clinical case for broad use in a large high-risk population. Like statins, it works as long as it is taken. Like statins, the debate is now less about whether it works than about who gets it, how, and at what cost. Tirzepatide loses more weight. Retatrutide loses still more. But the deepest evidence base — the one with outcomes that matter most to patients and physicians — still belongs to semaglutide.
Sources
  1. Wilding JPH et al. STEP 1. NEJM, 2021;384:989–1002. pubmed.ncbi.nlm.nih.gov/33567185
  2. Lincoff AM et al. SELECT. NEJM, 2023;389:2221–2232. pubmed.ncbi.nlm.nih.gov/37952131
  3. Perkovic V et al. FLOW. NEJM, 2024;391:109–121. pubmed.ncbi.nlm.nih.gov/38785209
  4. Marso SP et al. SUSTAIN-6. NEJM, 2016;375:1834–1844.
  5. Kosiborod MN et al. STEP-HFpEF. NEJM, 2023;389:1069–1084.
  6. Rubino D et al. STEP 1 extension. JAMA, 2021;325:1414.
  7. Colhoun HM et al. SELECT HbA1c subanalysis. Diabetes Care, 2024;47(8):1360–1369.
  8. Wang W et al. Semaglutide and Alzheimer's: target trial emulation. Alzheimer's & Dementia, 2024;20:8661–8672.
  9. Cummings JL et al. EVOKE/EVOKE+. The Lancet, March 2026. doi.org/10.1016/S0140-6736(26)00459-9
  10. Gabery S et al. Semaglutide neural pathways. JCI Insight, 2020. insight.jci.org/articles/view/133429
  11. Weghuber D et al. STEP TEENS. NEJM, 2022;387:2245–2257.
  12. Bliddal H et al. Semaglutide in knee osteoarthritis. NEJM, 2024;391:1573–1583.
  13. Pratley R et al. FLOW heart failure analysis. JACC, 2024;84(17):1615–1628.
  14. Aronne LJ et al. SURMOUNT-5. NEJM, 2025;393:26–36.
  15. Jastreboff AM et al. SURMOUNT-1. NEJM, 2022;387:205–216.
  16. Eli Lilly / TRIUMPH-4. Retatrutide Phase 3, December 2025. investor.lilly.com
  17. Sanyal AJ et al. Retatrutide for MASLD. Nature Medicine, 2024;30:2037–2048.
  18. FDA. Wegovy approval, June 2021. fda.gov
Science & Medicine Desk  ·  All external links open in a new tab  ·  2025–2026